ÂÜÀòÂÒÂ×

Dr. Hedley is president and chief operating officer at TESARO, an oncology-focused pharmaceutical company she co-founded in 2010 and that was later acquired by GSK. She currently serves on the board of directors of biopharmaceutical company, Millendo Therapeutics, Inc.

Previously, she served as executive vice president of operations and chief scientific officer at biotechnology company, Abraxis BioScience, Inc. She was also executive vice president of Eisai Corporation of North America following the company’s acquisition of MGI PHARMA, Inc. Before that she served in various positions at MGI PHARMA, Inc., most recently as executive vice president and chief scientific officer. Dr. Hedley also co-founded and served as the president and CEO of ZYCOS, Inc., a biotechnology company that was acquired by MGI PHARMA, Inc. in 2004. She has also previously served on the board of directors of TESARO, Inc., bluebird bio, and Receptos, Inc., which was acquired by Celgene Corp. in August 2015.

Dr. Hedley received a B.S. in microbiology from Purdue University and a Ph.D. in Immunology from the University of Texas, Southwestern Medical Center.